Nitiraj Engineers Regulatory Approval

Nitiraj Engineers Management Change

Nitiraj Engineers Limited has announced the re-appointment of Mr. Yi Hung Sin as an Executive Director for a five-year term, effective September 28, 2026.

Nitiraj Engineers Annual General Meeting

Nitiraj Engineers Limited conducted its 27th Annual General Meeting on September 28, 2026. The meeting covered routine items including financial statement adoption and auditor remuneration.

Nitiraj Engineers Other Announcement

Nitiraj Engineers informed shareholders with unregistered emails about accessing the AGM notice and Annual Report for FY 2025-26 via its website.

Nitiraj Engineers Annual General Meeting

Nitiraj Engineers approved its Annual Report and scheduled the 27th Annual General Meeting for September 28, 2026.

Nitiraj Engineers Board Meeting Date

Nitiraj Engineers Limited has scheduled a board meeting for September 4, 2026. The meeting agenda includes the consideration of various other business matters.

Nitiraj Engineers Q1 FY27 Results: Turns Profitable, Net Profit ₹1 Cr

Nitiraj Engineers Ltd reported revenue from operations of ₹18.8 Cr (+79.0% YoY) and net profit of ₹1 Cr for Q1 FY27.

Key figure

Net profit ₹1 Cr

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.